Suggested guidelines for determining the trough-to-peak ratio of antihypertensive drugs

American Journal of Hypertension

Volumn 9, Issue 10 PART I, 1996, Pages

  Myers, Martin G ^a,b  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Antihypertensive therapy; Hypertension; Treatment; Trough to peak ratio

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; HUMAN; HYPERTENSION; PRIORITY JOURNAL; RELIABILITY;

ANTIHYPERTENSIVE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPERTENSION; PRACTICE GUIDELINES;

EID: 0029856097     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/0895-7061(96)00267-1     Document Type: Review

References (19)

1. Rose M, McMahon FG: Some problems with antihypertensive drug studies in the context of the new guidelines. Am J Hypertens 1990;3:151-155.
2. Draft of the Proposed Guidelines for the Clinical Evaluation of Antihypertensive Drugs. Food and Drug Administration, Division of Cardio-Renal Drug Products, Rockville, MD.
3. Elliott HL, Meredith PA: Methodologic considerations in the calculation of the trough:peak ratio. J Hypertension 1994;12(suppl 8)S3-S7.
4. Myers MG: Trough-to-peak ratio and 24 hour blood pressure control: methodologic issues. Am J Hypertens 1995;8:214-219.
5. Palatini P, Mormino P, Canali C, et al: Factors affecting ambulatory blood pressure reproducibility: results of the Harvest Trial. Hypertension 1994;23:211-216.
6. Mancia G, Omboni S, Parati G, et al: Lack of placebo effect on ambulatory blood pressure. Am J Hypertens 1995;8:311-315.
7. Prasad N, MacFayden RJ, Ogston SA, MacDonald TM: Elevated blood pressure during the first two hours of ambulatory blood pressure monitoring: a study comparing consecutive twenty-four monitoring periods. J Hypertension 1995;13:291-295.
8. Cirillo VJ, Gomez HJ, Solonen J, et al: Lisinopril: dose-peak effect relationship in essential hypertension. Br J Clin Pharmacol 1988;25:533-538.
9. Gourley S, NcNeil J, Forbes A: Differences in the acute and chronic antihypertensive effects of lisinopril and enalapril assessed by ambulatory blood pressure monitoring. Clin Exp Hypertens 1993;15:71-89.
10. Bainbridge AD, Herlihy O, Meredith PA, Elliott HL: A comparative assessment of amlodipine and felodipine ER: pharmacokinetic and pharmacodynamic indices. Eur J Clin Pharmacol 1993;45:425-430.
11. Fariello R, Boni E, Corda L, et al: Extended release felodipine in essential hypertension. Am J Hypertens 1991;4:27-33.
12. Weber MA, Goldberg AI, Faisons EP, et al: Extended-release felodipine in patients with mild to moderate hypertension. Clin Pharmacol Ther 1994;55:346-352.
13. Leenen FHH, Fourney A, Tanner J: Persistence of antihypertensive effect after interruption of therapy with calcium antagonist with long (amlodipine) vs short (diltiazem) elimination half-life (abst). Am J Hypertens 1995;8:68A.
14. Collins R, Peto R, MacMahon S, et al: Blood pressure, stroke and coronary heart disease. Lancet 1990; 335:827-838.
15. Ford NF, Fulmor IE, Nichola PS, et al: Fosinopril monotherapy: relationship between blood pressure reduction and time of administration. Clin Cardiol 1993; 16:324-330.
16. Neutel JM, Schnaper H, Cheung DG, et al: Antihypertensive effects of beta-blockers administered once daily: 24-hour measurements. Am Heart J 1990; 120:166-171.
17. Zanchetti A, on behalf of the Italian Nifedipine GITS Study Group: Trough: peak ratio of the blood pressure response to dihydropyridine calcium antagonists. J Hypertens 1994;12(suppl 8):S97-S106.
18. Weber MA, Cheung DG, Laddu AR, Luther RR: Antihypertensive dose-response relationships: studies with the selective alpha-1 blocking agent terazosin. Am Heart J 1991;122:905-910.
19. Lipicky RJ: Trough:peak ratio: the rationale behind the United States Food and Drug Administration recommendations. J Hypertens 1994;12(suppl 8):S17-S19.